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Abstract
BACKGROUND: Non-variceal upper gastrointestinal bleeding (NVUGIB) is a life-threatening emergency that requires 
an urgent management. Antiplatelet (e.g., aspirin) and anticoagulant drugs are widely chronically used in various 
cardiac and coronary artery diseases. These drugs increase the risk of NVUGIB as they may cause ulceration of the 
upper gastrointestinal (GI) mucosa directly or may cause bleeding or rebleeding. The management of NVUGIB is 
complicated as the risk between GI bleeding episodes and cardiovascular attacks needs to be well managed.
AIM: The aim of this study is to determine the impact of antiplatelets (aspirin) and anticoagulants use on the morbidity, 
mortality, and clinical outcomes in patients presented with non-variceal GI bleeding.
PATIENTS AND METHODS: A total of 105 patients presented with melena and/or hematemesis and diagnosed 
by upper GI endoscopy were enrolled in a prospective cohort study. Patients were sub-grouped according to their 
use of antiplatelets, anticoagulants, or none (controls). Patients were excluded if they had portal hypertension or 
nonsteroidal anti-inflammatory drugs (NSAIDs) use and divided into five groups: Group I – patients who had not 
taken anticoagulants and antiplatelet; Group II – patients on heparin, warfarin, and LMWH only; Group III – patients 
on aspirin only; Group IV – patients on clopidogrel and ticlopidine with or without aspirin; and Group V – patients 
on combined anticoagulants and antiplatelet. All patients were subjected to clinical, laboratory (complete blood 
count, liver function tests, renal function tests, prothrombin time, and partial thromboplastin time), and endoscopic 
investigations. Clinical details were reported including admission, blood transfusion, rebleeding, and mortality.
RESULTS: Full medical history revealed that 43 patients were diabetic, 45 patients were cardiac, and 67 patients were 
hypertensive. Regarding the history of analgesic drug intake, 38 patients used NSAIDs and 29 of them used non-selective 
NSAIDs and 8 patients used selective NSAIDs. There were non-significant differences among the studied groups with 
NVUGIB regarding sex, hematemesis only presentation, melena only presentation, liver function tests, and endoscopic 
findings. On the other hand, there were statistically significant differences between the studied groups with NVGIB regarding 
increasing age, NSAIDs use whatever selective or non-selective, decrease level of HB, WBCs, serum albumin, bleeding 
profile, kidney function tests, clinical presentation in the form of hematemesis and melena, need for blood transfusion, 
history of associated diseases, especially being cardiac patients, rebleeding after 6 and 12 months, and mortality.
CONCLUSION: Aspirin intake may be associated with less favorable clinical outcomes in patients with NVUGIB, 
while combined anticoagulants and antiplatelets seem to be associated with the worse outcomes.
Introduction
Non-variceal upper gastrointestinal bleeding 
(NVUGIB) is a critical clinical condition that requires 
an urgent management [1], [2]. It remains a clinically 
important due to the increase in the proportion of elderly 
population, use of nonsteroidal anti-inflammatory drugs 
(NSAIDs) [3].
The incidence of upper gastrointestinal bleeding 
(UGIB) is 2-fold greater in males than in females, in all 
age groups; however, the death rate is similar in both 
sexes [4].
The initial laboratory tests include a blood count, 
international normalized ratio, partial thromboplastin 
time, electrolytes, creatinine, and blood typing in case 
transfusion is necessary [5].
Management of NVUGIB (Figure 1) [6]
Figure 1: Algorithm for the management of acute gastrointestinal 
hemorrhage. HDU: High dependency unit, NSAIDs: Nonsteroidal 
anti-inflammatory drugs, SRH: Stigmata of recent hemorrhage 
(NICE Clinical Guideline, 2015) [6]
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Resuscitation
The first priority is to correct fluid losses and 
restore blood pressure. Thus, intravenous (IV) access 
is a must [7].
Blood transfusion
The timing and amount of blood transfusions are 
valuable. It is accepted that patients with a hemoglobin 
level of ≤7 g/dL should receive a transfusion, whereas 
it is rarely indicated in patients with a hemoglobin level 
of ≥10 g/dL [8].
Pre-endoscopic care
Recent consensus suggests that nasogastric 
lavage is not helpful for diagnosis, prognosis [9], [10]. 
Pre-endoscopic use of proton-pump inhibitors (PPIs) is 
highly important [11].
Endoscopy
It is the principle diagnostic tool in UGIB and 
hemostatic therapy. While diagnostic endoscopy in 
clinically stable patients without relevant comorbidity is 
safe, complications may occur [9].
There are various endoscopic techniques: 
injection with epinephrine; clip application; 
thermocoagulation, argon plasma coagulation or injection 
with alcohol; fibrin; or thrombin glue [12].
The combination of epinephrine injection with 
one of the above-mentioned therapies significantly 
reduces rebleeding, need for surgery, and mortality [13].
Second look endoscopy has to be outweighed 
with potential risks [8]. On the contrary, another 
cost-effectiveness study [14] found endoscopy is more 
effective and less expensive.
The highest risk for rebleeding in patients 
treated with a combination of endoscopic and PPI 
therapy is within the first 72 h after the initial bleeding 
episode [15,16].
Medical therapy after endoscopy
IV bolus followed by infusion of high-dose 
PPI reduces recurrent bleeding, need for repeated 
endoscopy, surgery, and blood transfusion [17], [18]. 
However, in patients with lower risk standard, PPI 
therapy (e.g., oral PPI once daily) is enough [19].
Other considerations
Surgery offers a better chance to secure 
hemostasis [20]. Angiographic embolization should be 
considered as an alternative to surgery [21].
Helicobacter pylori
The successful eradication of an associated 
H. pylori infection lowers the risk of reappearance of an 
ulcer in the 1st year after hemorrhage to <5% [22].
It is well known that H. pylori testing might 
reveal false-negative results in the setting of an acute 
bleeding episode [23].
NSAID use
In patients with NSAID-associated bleeding ulcers, 
the need for NSAIDs should be carefully assessed. In 
patients who must continue on NSAIDs, a cyclooxygenase-2 
selective NSAID plus PPI offers the best available upper 
gastrointestinal (GI) protection [24], [25], [26].
NVUGIB and antiplatelet and 
antithrombotic
Nowadays, many patients receive 
chronic antithrombotic therapy for various cardiac 
diseases (Figure 2) [27].
Figure 2: Causes of non-variceal upper gastrointestinal bleeding
The relative risk for UGIB increases up to 10% 
in patients treated with these therapies [28], [29], [30]. 
This complication puts affected patients into an acutely 
life-threatening situation because the mortality from UGIB 
ranges from 1% to 13% [31], [32], [33]. Therefore, therapy 
with ASA or clopidogrel in patients with cardiovascular 
risk factors should be restarted as soon as possible [8].
Anticoagulant therapy has historically consisted 
of heparins for the treatment of acute thrombosis and 
Vitamin K antagonists (VKA) for long-term treatment [34].
VKAs are indicated in patients with atrial 
fibrillation, thromboembolic venous disease, or a 
mechanical heart valve, while, recently, the novel 
oral anticoagulants, such as dabigatran, rivaroxaban, 
and apixaban, have been used in non-valvular atrial 
fibrillation and venous thromboembolism [35].
The indications of antiplatelet drugs use are in 
the management of thrombotic diseases include stroke, 
acute myocardial infarction, acute coronary syndrome, 
and angina [36].
Clopidogrel requires cytochrome P450 isoenzyme 
CYP2C19 to be converted to its active metabolite [37]. PPI 
and clopidogrel compete for the same cytochrome P450 
isoenzyme [38], [39], [40], [41], [42], but other studies did 
not reveal an increase in cardiovascular events [42], [43].
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In the current study, we aim to determine 
the impact of antiplatelets and anticoagulants on the 
morbidity, mortality, and clinical outcomes in patients 
presented with non-variceal GI bleeding.
Patients and Method
This study included 105 patients admitted in 
Ain Shams University Hospitals and Ahmed Maher 
Teaching Hospital whom presented with hematemesis 
and/or melena and diagnosed by upper GI endoscopy 
and divided into five groups according to the drug 
intake.
Group I: Patients who had not taken anticoagulants and 
antiplatelet.
Group II:  Patients on anticoagulants (heparin, warfarin, 
and low-molecular-weight heparin [LMWH] only).
Group III: Patients on aspirin only.
Group IV:  Patients on clopidogrel and ticlopidine with or 
without aspirin.
Group V:  Patients on combined anticoagulants and 
antiplatelet.
Patients were excluded if there were 
other causes of UGIB (esophageal varices, portal 
hypertensive gastropathy, and gastric varices if the 
bleeding source was gastric cancer, if bleeding was 
associated with endoscopic procedures such as 
endoscopic mucosal resection, or if bleeding occurred 
in the lower GI tract).
Methods
A written consent was taken from all 
participants and oral explanation of the whole 
procedure, in which they will be involved in. 
A full history taking including age-associated 
medical conditions as diabetes mellitus, cardiac, 
hypertension, gender, history of drug intake 
(NSAID) and antithrombotic drugs, and history of 
any inserted cardiac prostheses that might be a 
causal relationship to the hemorrhage (coronary 
stents and platelet aggregation inhibitors, cardiac 
valvular prostheses and anticoagulants, and aortic 
prostheses with the risk of an aortointestinal 
fistula). Full examination and full laboratories were 
done, including complete blood count, liver function 
tests (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], serum albumin, and total 
and direct bilirubin), renal function tests (serum 
creatinine and blood urea), and prothrombin time 
and partial thromboplastin time. Upper endoscopy 
was done by expert (one expert in each hospital to 
decrease the bias) endoscopists using fiber-optic 
endoscopy after good sterilization. Initial assessment 
and resuscitation according to the amount of bleeding 
(mild-moderate-massive), urgently or within 24–48 h 
(all patients were intravenously administered PPIs) 
was performed. Then, follow-up of our studied patients 
for rebleeding and mortality after 6 and 12 months 
after discharge from the hospital was done.
Statistical analysis
The collected data were tabulated and 
statistically analyzed using SPSS software 
(Statistical Package for the Social Sciences, 
version 16, SPSS Inc., Chicago, IL, USA). For 
quantitative data, the range, mean, and standard 
deviation were calculated. For qualitative data, the 
comparison between two groups was done by Chi-
square test. For comparison between more than 
two means of data, F value of ANOVA test was 
calculated. Significance was at p < 0.05 for the 
results of the tests of significance.
Results
The study included 105 patients who were 
divided into five groups: Group I: Thirty patients 
(14 men [46.6%] and 16 women [53.3%]) who had not 
taken anticoagulants and antiplatelet, their mean age 
of 44.56 ± 7.63. Group II: Twenty patients on heparin, 
warfarin, and LMWH only. They were 8 males (40%) 
and 12 females (60%) with their mean age of 45.72 
± 6.84. Group III: Twenty-five patients on aspirin only 
who were 12 men (48%) and 13 women (52%) with a 
mean age of 53.50 ± 5.39. Group IV: Fifteen patients 
(9 men [60%] and 6 men [40%]) on clopidogrel and 
ticlopidine with or without aspirin with a mean age 
of 55.19 ± 6.47. Group V: Fifteen patients 10 male 
(66.6%) and 5 female (33.3%) who were on combined 
anticoagulants and antiplatelet with their mean age of 
56.46 ± 7.35 (Table 1).
Table 1: Demographic findings of the studied patients
Group 
number
I (30) II (20) III (25) IV (15) V (15) p value
Age 
(mean±SD)
44.56±7.63 45.72±6.84 53.50±5.39 55.19±6.47 56.46±7.35 0.000
Sex
Male  
n (%)
14 (46.66%) 8 (40%) 12 (48%) 9 (60%) 10 (66.66%) 0.519
Female  
n (%)
16 (53.33%) 12 (60%) 13 (52%) 6 (40%) 5 (33.33%)
SD: Standard deviation.
The study revealed that the sex among 
the studied groups was not statistically significant 
(p = 0.519). Age of the patients was statistically 
significant (p = 0.000), as shown in Table 1.
According to the laboratory profile of the 
studied patient groups, all were statistically significant 
except for ALT, AST, PLT, and total bilirubin which were 
statistically insignificant, as shown in Table 2.
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and the need to blood transfusion among the studied 
groups, p = 0.003), as shown in Table 6 and Figure 4.
Figure 3: Upper gastrointestinal endoscopic findings of our studied 
patients
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Table 4: Presenting bleeding symptoms
Group I (30) II (20) III (25) IV (15) V (15) χ2 p value χ2 p value
Hematemesis n 22 11 17 6 5 2.756 0.599 21.412 0.044
% 73.33 55 68 40 33.33
Melena n 7 4 6 3 2 0.535 0.970
% 23.33 20 24 20 13.33
Hematemesis and melena n 1 5 2 6 8 13.03 0.011
% 3.33 25 8 40 53.33
Then, we followed up our studied patients 
after 6 and 12 months after the first attack of NVUGIB 
and the discharge from the hospital. We followed up 
the rebleeding episodes and occurrence of mortality 
while using their medications, we noticed statistically 
significant values among the studied patients’ groups, 
as illustrated in Table 7.
Discussion
GI bleeding is a serious problem, especially in 
the elderly and/or multimorbid patients. On the one hand, 
any anticoagulant and antiplatelet treatment should be 
discontinued to help stopping the acute bleeding. On 
the other hand, discontinuing this type of therapy can 
significantly increase the risk for cardiovascular or 
cerebrovascular complications due to the underlying 
disease [44].
Table 2: Biochemical results of our studied patients
Group (n) I (30) II (20) III (25) IV (15) V (15) p value
Hgb 10.83±1.32 8.43±1.54 9.67±1.46 8.26±0.74 8.65±1.63 0.000
WBCs 7.25±1.53 7.38±1.56 8.45±1.24 8.16±1.37 8.84±1.74 0.002
PLT 194.75±83.56 185.54±74.33 188.52±72.23 198.87±63.59 233.82±75.93 0.364
PT 12± 0.09 12.14±0.35 12.10±0.21 12.25±0.47 12.34±0.36 0.004
PTT 30.41±2.65 33.65±3.71 32.26±4.42 35.25±3.86 35.55±4.52 0.000
INR 1.00±0.12 1.14±0.14 1.12±0.13 1.21±0.05 1.23±0.07 0.000
ALT 22.0±5.76 24.00±7.36 23.0±8.39 25.0±8.85 25.0±9.88 0.667
AST 30.0±6.67 33.0±6.38 32.0±7.27 33.0±6.53 34.0±7.46 0.342
T. bil. 0.84±0.23 1.21±0.67 0.86±0.43 0.89±0.75 1.02±0.13 0.068
D. bil. 0.17±0.06 0.33±0.18 0.18±0.15 0.27±0.23 0.48±0.25 0.000
S. alb. 4.23±0.44 3.84±0.35 4.12±0.51 3.86±0.52 3.92±0.65 0.027
S. cr. 0.8±0.10 0.9±0.14 0.87±0.12 0.92±0.11 0.98±0.12 0.000
Bl. urea 26.52±5.41 30.0±6.82 28.6±4.71 32.45±5.83 31.36±5.78 0.008
Hgb: Hemoglbin, WBCs: White blood cells, Plt: Platelet, PT: Prothrombin level, PTT: Partial thromboplastin time, INR: International normalized ratio, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, 
T. bil.: Total bilirubin, D. bil.: Direct bilirubin, S. alb.: Serum albumin, S. cr.: Serum creatinine, Bl. urea: Blood urea.
Regarding the medical history of the patients, 
being diabetic or hypertensive or cardiac patient was 
statistically significant (Table 3).
Our studied patients were presented 
by NVUGIB, which was either in the form of 
hematemesis or melena or both together and was 
the statistically significant symptom (p = 0.011) as 
shown in Table 4.
Regarding the management of NVUGIB, UGI 
endoscopy had been performed and the results of the 
endoscopy are shown in Figure 3 and Table 5, which 
showed no statistical significance.
According to the management of UGIB, the 
need for blood transfusion was statistically significant 
when compared to the studied groups (no need to 
blood transfusion among the studied groups, p = 0.001 
Figure 4: Need for blood transfusion in the management of our 
studied groups
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Table 3: History of other associated diseases
Group (n) I (30) II (20) III (25) IV (15) V (15) p value
DM n 3 12 8 9 11 0.0276
% 10 60 32 60 73.33
HTN n 6 16 17 13 15 0.037
% 20 80 68 86.66 100
Cardiac n 3 4 8 15 15 0.000
% 10 20 32 100 100
DM: Diabetes mellitus, HTN: Hypertension.
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Table 5: UGI endoscopic findings of our studied patients
Group number I (30) II (20) III (25) IV (15) V (15) χ2 p value
Esophageal erosions 23 16 19 9 7 1.265 0.867
Gastritis 26 18 16 8 12 1.479 0.830
GU 1 3 5 6 4 6.952 0.138
DU 2 2 3 5 1 5.188 0.268
GU: Gastric ulcer, DU: Duodenal ulcer.
Monotherapy with antiplatelet agents or 
anticoagulants is associated with an increasing risk of 
UGIB [45]. Therefore, these medications in patients with 
UGIB should be discontinued for days, even weeks, and 
during and after bleeding episode [46].
Table 6: Need for blood transfusion in the management of 
NVUGIB
Group number I (30) II (20) III (25) IV (15) V (15) χ2 p value χ2 p value
No need 27 13 6 2 1 17.419 0.001 46.835 0
% 90 65 24 13.33 6.66
Need 3 7 19 13 14 15.906 0.003
% 10 35 76 86.66 93.33
NVUGIB: Non-variceal upper gastrointestinal bleeding.
Although the continuation of low-dose aspirin 
will increase the risk of rebleeding, it has been reported 
to be able to reduce all causes of mortality rate in a 
small sample of patients [47].
Table 7: Rebleeding and mortality after 6 months and 12 months
Group I (30) II (20) III (25) IV (15) V (15) p value
Rebleeding after 6 months
Yes 1 3 4 5 5 0.046
No 29 17 21 10 10
Mortality after 6 months
Yes 0 1 0 1 3 0.032
No 30 19 25 14 12
Rebleeding after 12 months
Yes 1 3 2 4 6 0.046
No 29 17 22 11 9
Mortality after 12 months
Yes 0 1 0 1 4 0.032
No 30 19 25 14 11
The current evidence on the effects of aspirin or 
anticoagulants on the clinical outcomes of patients with 
UGIB is controversial, as Sung et al. [47] have reported 
that aspirin decreases the mortality of patients while 
Ortiz et al. [48] have suggested that these drugs have 
no effects. Similarly, conflicting results on the effects of 
anticoagulants such as warfarin have been reported [49].
In this study, we aimed to determine the 
impact of antiplatelets (aspirin) and anticoagulants on 
the clinical outcomes of 105 patients (53 males and 
52 females) aged 36–62 years. Forty-three were diabetic 
patients, 45 patients were cardiac, and 67 patients 
were hypertensive; 38 patients used NSAIDS and 29 
of them used non-selective NSAIDS and 8 patients 
used selective NSAIDS who were hospitalized due to 
NVUGIB and followed up after 6 and 12 months for 
rebleeding attacks and mortality outcomes.
Statistically significant differences were found 
among the studied patients regarding age, history 
of associated disease (especially, cardiac), use of 
analgesics, clinical presentation of NVUGIB (both 
hematemesis and melena presenting together), HB, 
WBCs, bleeding profile, kidney function, serum albumin, 
need for blood transfusion, rebleeding after 6 and 
12 months, and mortality, these results are in conformity 
with Hearnshaw et al. [50] and Modaber et al. [51].
Aging and comorbidities are known predictors of 
mortality and adverse clinical outcomes [46]. The mortality 
rate in elderly patients with NVUGIB is increased and the 
reason is unclear, it may be due to that elderly patients are 
more prone to have complex comorbidities and be more 
susceptible to physiological changes associated with 
acute bleeding episodes than younger patients. Therefore, 
more careful follow-up with intensive monitoring is needed 
in this population group following bleeding events.
In our study, we noticed that the patient group 
on aspirin only had a less mortality and rebleeding 
events were lower than in other patient groups. Similar 
protective effects of aspirin against UGIB-related 
deaths, besides, its cardiovascular benefits had been 
reported by Sung et al. [47] Wehbeh et al. [52], and 
Souk et al. [53] and also in a study that included both 
peptic and non-peptic ulcer patients [49].
On the contrary, Ahsberg et al. [54] have 
reported non-statistically significant association between 
aspirin use and mortality although those taking NSAIDs 
were included. In addition, recently, Luo et al. [55] found 
that the use of aspirin increases the risk of 1st time 
NVUGIB in general population after adjusting for age, 
gender, H. pylori infection, underlying comorbidities, 
and concomitant use of certain medications. Moreover, 
Taha et al. [56] noticed that a low-dose aspirin intake 
is associated with longer hospital stays and increased 
requirements of blood transfusion, but the study 
included those with variceal bleeding. However, Taha 
et al. [57] stated that in NVUGIB, the antiplatelet and 
anticoagulant activities are associated with older age 
and greater need for admission, transfusion, and 
rebleeding. The outcomes were more in users of 
anticoagulants even after adjustment for age, sex, and 
endoscopy, but with an insignificant effect on mortality.
Aspirin use was a predictor for short length 
of hospital stay in our study, which is consistent with 
a better overall outcome for those patients. This is 
different from what has been reported, which might be 
due to varied study designs [47] or the patients included 
in the study (both peptic ulcer disease [PUD] and non-
PUD-related UGIB) [48].
On the other hand, Lanas et al. [49] observed 
that anticoagulants use to increase the requirements 
for blood transfusion and are associated with a longer 
hospital stay. Marmo et al. [4] showed that heparin, but 
not warfarin, increases mortality risk.
In our studied patients groups, we noticed that 
the most common cause of NVUGIB by endoscopy was 
gastritis followed by esophageal erosions then GU, but 
all with no statistically significant difference. This was 
not in agreement with Telaku et al. [58] who stated that 
the most common cause of NVUGIB was peptic ulcer.
Rebleeding is a predictor of mortality [50]. 
Rubin et al. [59] have suggested that the risk of 
rebleeding is not affected by antithrombotic. However, 
aspirin continuation seems to be associated with its 
increased risk of rebleeding.
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Non-bleeding related causes accounted for 
most deaths, which is in accordance with Wong et al. [60] 
who concluded that the number of patients who died of 
acute renal failure in their study was high enough to be 
considered as an independent risk factor of death [60], 
while we considered as a part of multiorgan failure.
Malignancies were also responsible for the 
non-bleeding-related deaths which were observed 
during follow-up periods. That was in agreement with 
the results of Marmo et al. [61], while cardiovascular 
causes were high [61].
Conclusion
Our study suggested that aspirin intake may 
be associated with less favorable clinical outcomes in 
UGIB, while combined anticoagulants and antiplatelet 
seem to be associated with worse clinical outcomes.
Recommendations
• Study a larger scale of patients in many centers 
to decrease the bias.
• Patients on low-dose ASA should be tested for 
H. pylori.
• A discussion and ultimately a consensus 
among gastroenterologists and cardiologists 
with respect to the benefit-risk ratios are 
desirable.
• Adding a questionnaire to assess the quality 
of life before and after being admitted and 
endoscopically and medically managed during 
the episode of NVUGIB.
Limitations
Our study has some limitations and pitfalls:
• The small number of studied patients as we 
selected the patients with an emergency 
presentation (hematemesis and/or melena) 
and need to follow them up for a long time, 
which can be avoided if the study was 
retrospective.
• H. pylori analysis for the studied patients with 
NVUGIB which was not performed.
• Lack of endoscopic scoring system.
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